Literature DB >> 21572033

Genetic segregation of inflammatory lung disease and autoimmune disease severity in SHIP-1-/- mice.

Mhairi J Maxwell1, Mubing Duan, Jane E Armes, Gary P Anderson, David M Tarlinton, Margaret L Hibbs.   

Abstract

Alternatively activated M2 macrophages are implicated as both regulators and agents of lung disease, but their control is poorly understood. SHIP-1 is a 5' inositol phosphatase that negatively regulates the PI3K signaling pathway implicated in inflammation. SHIP-1-deficient mice have defects in hematopoiesis and B cell development, and die prematurely due to consolidation of lungs with M2-skewed macrophages. SHIP-1 is thought to restrain M2 macrophage polarization, with deregulated M2 skewing coinciding with severe lung disease in SHIP-1-deficient mice. To determine the influence of genetic background on the lung phenotype in SHIP-1(-/-) mice, we backcrossed the SHIP-1 null mutation onto C57BL/6 (Th2-resistant) and BALB/c (Th2-prone) backgrounds. Remarkably, we found that inflammatory lung disease was severe in C57.SHIP-1(-/-) mice, but absent in BALB.SHIP-1(-/-) mice. C57.SHIP-1(-/-), but not BALB.SHIP-1(-/-) mice had greatly increased myeloid progenitors, myeloid hyperplasia, markedly enhanced numbers of activated alveolar macrophages, and elevated amounts of Th2 and proinflammatory cytokines in bronchoalveolar lavage fluid and serum, suggesting that deregulated cytokine production induced disease. C57.SHIP-1(-/-) mice also developed severe B cell-dependent autoimmune disease, which was markedly attenuated on the BALB/c background. These data demonstrate that, contrary to current concepts, loss of SHIP-1 alone is not sufficient to cause lung inflammation, with disease only manifest on a permissive genetic background. This finding questions the nature of the lung disease in SHIP-1(-/-) mice, suggesting that its M2 classification is not strictly correct. Future identification of disease-promoting loci might reveal determinants of comorbid lung disease and autoimmunity and uncover potentially useful therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21572033     DOI: 10.4049/jimmunol.1004185

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.

Authors:  Shannon K O'Neill; Andrew Getahun; Stephen B Gauld; Kevin T Merrell; Idan Tamir; Mia J Smith; Joseph M Dal Porto; Quan-Zhen Li; John C Cambier
Journal:  Immunity       Date:  2011-11-09       Impact factor: 31.745

2.  Granulocyte-CSF links destructive inflammation and comorbidities in obstructive lung disease.

Authors:  Evelyn Tsantikos; Maverick Lau; Cassandra Mn Castelino; Mhairi J Maxwell; Samantha L Passey; Michelle J Hansen; Narelle E McGregor; Natalie A Sims; Daniel P Steinfort; Louis B Irving; Gary P Anderson; Margaret L Hibbs
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

Review 3.  Signaling mechanisms regulating B-lymphocyte activation and tolerance.

Authors:  Elias Hobeika; Peter J Nielsen; David Medgyesi
Journal:  J Mol Med (Berl)       Date:  2015-01-29       Impact factor: 4.599

4.  Excessive CD11c+Tbet+ B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus.

Authors:  Wenqian Zhang; Huihui Zhang; Shujun Liu; Fucan Xia; Zijian Kang; Yan Zhang; Yaoyang Liu; Hui Xiao; Lei Chen; Chuanxin Huang; Nan Shen; Huji Xu; Fubin Li
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-26       Impact factor: 11.205

5.  AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis.

Authors:  Jennifer Cross; Grant R Stenton; Curtis Harwig; Csaba Szabo; Tiziana Genovese; Rosanna Di Paola; Emanuale Esposito; Salvatore Cuzzocrea; Lloyd F Mackenzie
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

6.  The structural wedge domain of the receptor-like tyrosine phosphatase CD45 enforces B cell tolerance by regulating substrate specificity.

Authors:  Julie Zikherman; Ramya Parameswaran; Michelle Hermiston; Arthur Weiss
Journal:  J Immunol       Date:  2013-02-08       Impact factor: 5.422

7.  Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo.

Authors:  Grant R Stenton; Lloyd F Mackenzie; Patrick Tam; Jennifer L Cross; Curtis Harwig; Jeffrey Raymond; Judy Toews; David Chernoff; Thomas MacRury; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

8.  Role of SHIP1 in Invariant NKT Cell Development and Functions.

Authors:  Courtney K Anderson; Alexander I Salter; Leon E Toussaint; Emma C Reilly; Céline Fugère; Neetu Srivastava; William G Kerr; Laurent Brossay
Journal:  J Immunol       Date:  2015-07-31       Impact factor: 5.422

9.  SHIP-1 deficiency in the myeloid compartment is insufficient to induce myeloid expansion or chronic inflammation.

Authors:  M J Maxwell; N Srivastava; M-Y Park; E Tsantikos; R W Engelman; W G Kerr; M L Hibbs
Journal:  Genes Immun       Date:  2014-03-06       Impact factor: 2.676

10.  Background differences in baseline and stimulated MMP levels influence abdominal aortic aneurysm susceptibility.

Authors:  Matthew A Dale; Melissa K Suh; Shijia Zhao; Trevor Meisinger; Linxia Gu; Vicki J Swier; Devendra K Agrawal; Timothy C Greiner; Jeffrey S Carson; B Timothy Baxter; Wanfen Xiong
Journal:  Atherosclerosis       Date:  2015-10-08       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.